Sanbio B.V., an independent supplier and manufacturer of MONOSAN® products for research, and BenchSci, a life science machine learning company backed by Google’s AI fund, have entered into a partnership to provide scientists with high-quality research products for accelerating biomedical discoveries.
Immunohistochemistry (IHC) is one of the most common techniques to visualize tissue proteins with the help of enzymatically- or fluorescently-labeled antibodies. IHC is a popular technique not only among academic and industry scientists but also in the clinics to differentiate between healthy and morphologically abnormal or diseased tissue. While selecting IHC antibodies, it is crucial to consider the process of tissue preservation. For example, some antibodies require an additional antigen retrieval step when working with formalin-fixed or paraffin-embedded tissues. Additionally, poor-quality antibodies may have a propensity for random non-specific binding during IHC on frozen or fixed tissues, leading to questionable results.
Sanbio B.V.’s partnership with BenchSci aims to solve this problem by combining the company’s extensive catalog of specialized IHC antibody products under the brand name MONOSAN® with BenchSci’s inventive artificial intelligence platform. Using machine learning, BenchSci’s AI will not only identify published data for MONOSAN® products in open- and closed-access research papers, but will also display vendor-provided validation figures to allow scientists to find the right antibody that works in their experimental context.
Wilco van Hamond, CEO at Sanbio B.V., believes that the partnership with BenchSci will boost the discoverability and buyability of MONOSAN® products. “Through this unique collaboration, we are looking forward to helping scientists across the world run successful IHC experiments by providing highly specific and exclusive IHC antibodies,” says Wilco. Additionally MONOSAN® antibodies be used for IC, FC and WB.
“Sanbio B.V.’s vision to provide scientists with research products that meet the standards set for reliability, quality, and innovation is aligned with BenchSci’s commitment to providing scientists with the right, good-quality reagents using machine learning technology,” says Liran Belenzon, CEO, BenchSci. “We are very excited to partner with an established company like Sanbio B.V. to facilitate revolutionary breakthroughs towards the progression of better healthcare.”
About Sanbio B.V.
Sanbio B.V., based in Uden (the Netherlands) and established in 1978, is an independent supplier of life science products for research and diagnostics in the Benelux and represents a large number of innovative international companies. Sanbio is also the manufacturer and developer of antibodies and antibody-related products of its own brand MONOSAN®, suitable for basic and applied life sciences experiments. The MONOSAN® portfolio contains over 3000 monoclonal and polyclonal antibodies and reagents which are being developed and commercialized either in their own laboratories or in collaboration with some of the leading universities and research institutes throughout Europe and the United States. A complete range of specific and exclusive antibodies is brought together at their website: www.monosan.com.
About BenchSci
Backed by Google’s AI fund, Gradient Ventures, and built by life scientists for life scientists, BenchSci’s AI reads biomedical papers and maps their findings to navigate researchers to novel discoveries faster. Using data from more than 9 million publications, this map leverages the world’s most comprehensive, evidence-based biological knowledge graph. Unlike other bioinformatics tools, it helps researchers find unexpected connections, generate unconsidered hypotheses, discover novel insights, avoid redundant experiments, and adopt the best reagents and methods. This catalyzes faster, more cost-effective, and higher impact discoveries by academic and industry partners. BenchSci’s first product, an antibody knowledge engine, helps researchers find reliable antibodies up to 24x faster and use commercial antibodies up to 75% more cost-effectively. It now powers discoveries in 15 of the top 20 pharmaceutical companies and more than 2,000 academic institutions worldwide.
Contact us for more information